Table 3 Efficacy of second line gemcitabine and nab-paclitaxel
Median time to treatment failure, weeks | 12.0 (2.0–36.0) |
Median overall survival, weeks | 23.0 (2.1–85.4) |
Response by RECIST, n (%) | |
Partial response | 5 (17.9) |
Stable disease | 8 (28.6) |
Progressive disease | 12 (42.8) |
Inevaluable | 3 (10.7) |
Serologic response, n (%)a | |
CA 19-9 | 13 (46.4) |
CEA | 11 (39.3) |